Transactions & Cas
Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly
09.03.2017
Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.
After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.
Partager
Plus d'informations
bundespatentgericht.chContact
Schellenberg Wittmer conseille Emerald Technology Ventures dans l'obtention de sa licence FINMA
13.02.2024
Schellenberg Wittmer conseille Carne dans le cadre du transfert des activités de "Fund Management Services" pour tiers de GAM
01.02.2024
Schellenberg Wittmer conseille AXA dans le cadre du regroupement de ses trois fonds immobiliers
30.01.2024